Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of ...

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Moderna Inc. MRNA stock is trading lower after it rallied around 170% on Wednesday on upbeat data from individualized cancer ...

“It’s very exciting,” a melanoma expert said of the experimental cancer vaccine announced by pharmaceutical companies Moderna ...

Merck MRK is increasingly relying on the growing portfolio of newer products, recent acquisitions and pipeline candidates to ...

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

Adults at high risk of melanoma recurrence and spread were able to stay cancer-free with personalized vaccines made with mRNA ...

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...